More Syntara Limited news
Syntara LimitedASX: SNT

PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial

Oct 13, 2021 at 12:20 AM EDT · Issued by Syntara Limited

Filed with ASX · Oct 13, 2021 at 12:20 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/pxs-doses-first-patient-in-phase-2-bone-marrow-cancer-trial

Syntara Limited on 6ix

Story so far

  • PXS Cleared to Progress to Phase 2 Bone Marrow Cancer TrialOct 5, 2021
  • PXS Announces First Results in Bone Marrow Cancer TrialJun 29, 2021
  • First Patient Enrolled - Clinical Trial for Cancer TreatmentFeb 22, 2021

Earlier from Syntara

  • PXS Cleared to Progress to Phase 2 Bone Marrow Cancer TrialOct 4, 2021
  • Pharmaxis Treatment to Prevent Wound and Burns Scars ClearsAug 30, 2021
  • PXS Grants Exclusive Option to Develop High Payload InhalerAug 16, 2021
  • PXS Drug Decreases Tumour Burden in Liver Cancer ModelAug 4, 2021
  • PXS Sells Australian Distribution Rights for A$2mJun 30, 2021

Later from Syntara

  • Appendix 4C Cash Flow ReportOct 27, 2021
  • FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer StudyNov 8, 2021
  • Security Purchase PlanNov 24, 2021
  • Share Purchase PlanDec 20, 2021
  • PXS Collaborators Receive Government Grants of $1.4mJan 5, 2022
All Syntara news releases↗

Follow Syntara into a list and get an email when it puts out news.

Follow Syntara
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer